New erythromycin derivatives enhance <i>β</i>
-lactam antibiotics against methicillin-resistant <i>Staphylococcus aureus</i>

Li, Z.; He, Mai; Dong, Xiaojing; Lin, Haixin; Ge, Hui; Shen, Steven S.; Li, J.; Ye, Richard D.; Chen, D.

doi:10.1111/lam.12378

Cited by 9 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SIPI‐8294 was synthesized as previously reported (Li et al . ). Oxacillin was purchased from the National Institute for Food and Drug Control (NIFDC) of China.…”

Section: Methodsmentioning

confidence: 97%

“…The bacteria and plasmids used in this study are listed in Table S1. SIPI-8294 was synthesized as previously reported (Li et al 2015). Oxacillin was purchased from the National Institute for Food and Drug Control (NIFDC) of China.…”

Section: Bacterial Strains and Reagentsmentioning

confidence: 99%

“…Recent study has revealed that SIPI‐8294 has remarkable synergistic effect with β ‐lactam antibiotics against MRSA (Li et al . ). However, the mechanism for the synergistic effect of SIPI‐8294 and β ‐lactam antibiotics is still unclear.…”

Section: Introductionmentioning

confidence: 97%

“…SIPI-8294 (Shen et al 2012), as a new derivative of erythromycin, was synthesized by Shanghai Institute of Pharmaceutical Industry. Recent study has revealed that SIPI-8294 has remarkable synergistic effect with b-lactam antibiotics against MRSA (Li et al 2015). However, the mechanism for the synergistic effect of SIPI-8294 and b-lactam antibiotics is still unclear.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Mechanism of synergy between SIPI-8294 and β-lactam antibiotics against methicillin-resistant Staphylococcus aureus

Shao

Liu

et al. 2016

Letters in Applied Microbiology

Self Cite

View full text Add to dashboard Cite

This study is the first report on the mechanism of synergy between SIPI-8294 and β-lactams against MRSA on the molecular level. In this study, SIPI-8294 showed strong synergistic effects on β-lactam antibiotics both in vitro and in vivo owing to inhibiting mecA expression. As pivotal regulatory genes of mecA, mecR1 and mecI do not participate in SIPI-8294-mecA pathway and are not involved in the synergism of SIPI-8294 and β-lactams. The research indicates that it may be a promising strategy for combating MRSA infections with the combinations of SIPI-8294 and β-lactams. The research is important for structure modification and new drug development.

show abstract

“…SIPI‐8294 was synthesized as previously reported (Li et al . ). Oxacillin was purchased from the National Institute for Food and Drug Control (NIFDC) of China.…”

Section: Methodsmentioning

confidence: 97%

Section: Bacterial Strains and Reagentsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mechanism of synergy between SIPI-8294 and β-lactam antibiotics against methicillin-resistant Staphylococcus aureus

Shao

Liu

et al. 2016

Letters in Applied Microbiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…SIPI-8294 (Chinese patent CN201010273264 and CN201410131277) is a new derivative of erythromycin synthesized by the Shanghai Institute of Pharmaceutical Industry 25 . The chemical structures of SIPI-8294 and erythromycin are shown in Fig.…”

mentioning

confidence: 99%

Proteomic response of methicillin-resistant S. aureus to a synergistic antibacterial drug combination: a novel erythromycin derivative and oxacillin

Liu

Pai

Zhang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The use of antibacterial drug combinations with synergistic effects is increasingly seen as a critical strategy to combat multi-drug resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In this work, the proteome responses in MRSA under the stress of a sub-inhibitory dose of a synergistic drug combination of a novel erythromycin derivative, SIPI-8294, and oxacillin, were studied by label-free quantitative proteomics. Several control treatment groups were designed to isolate proteome responses potentially related to the synergy: (1) the non-synergistic drug combination of erythromycin and oxacillin, (2) SIPI-8294 only, (3) oxacillin only and (4) erythromycin only. Results showed that 200 proteins were differentially expressed in SIPI-8294/oxacillin-treated cells. Among these proteins, the level of penicillin binding protein 2a, the protein mainly responsible for oxacillin resistance in MRSA, was four times lower in the SIPI-8294/oxacillin group than in the erythromycin/oxacillin group, suggesting that SIPI-8294 may interfere with this known oxacillin resistance mechanism. Moreover, hierarchical clustering analysis of differentially expressed proteins under different treatments revealed that SIPI-8294/oxacillin elicits very different responses than the individual drugs or the non-synergistic erythromycin/oxacillin combination. Bioinformatic analysis indicated that the synergistic effect can be further traced to a disruption in oxidation-reduction homeostasis and cell wall biosynthesis.

show abstract

An Overview on the Recent Advances in the Treatment of Infected Wounds: Antibacterial Wound Dressings

Mirhaj

Labbaf

Tavakoli

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

A wound can be surgical cuts from an operation or due to accident and trauma. The infected wound, as a result of bacteria growth within the damaged skin, interrupts the natural wound healing process and significantly impacts the quality of life. Wound dressing is an important segment of the skincare industry with its economic burden estimated at $ 20.4 billion (in 2021) in the global market. The results of recent clinical trials suggest that the use of modern dressings can be the easiest, most accessible, and most cost‐effective way to treat chronic wounds and, hence, holds significant promise. With the sheer number of dressings in the market, the selection of correct dressing is confusing for clinicians and healthcare workers. The aim of this research is to review widely used types of antibacterial wound dressings, as well as emerging products, for their efficiency and mode of action. In this review, introducing antibiotics and antibacterial nanoparticles as two important and clinically widely used categories of antibacterial agents is focused. The perspectives and challenges for paving the way for future research in this field are also discussed.

show abstract

New erythromycin derivatives enhance β -lactam antibiotics against methicillin-resistant Staphylococcus aureus

Cited by 9 publications

References 20 publications

Mechanism of synergy between SIPI-8294 and β-lactam antibiotics against methicillin-resistant Staphylococcus aureus

Mechanism of synergy between SIPI-8294 and β-lactam antibiotics against methicillin-resistant Staphylococcus aureus

Proteomic response of methicillin-resistant S. aureus to a synergistic antibacterial drug combination: a novel erythromycin derivative and oxacillin

An Overview on the Recent Advances in the Treatment of Infected Wounds: Antibacterial Wound Dressings

Contact Info

Product

Resources

About